Emmett T. Cunningham, Jr., M.D., PhD., M.P.H
|
|
- Dorothy Wilkerson
- 6 years ago
- Views:
Transcription
1 ICO World Ophthalmology Roundtable on Leadership Development (WORLD) Five Trends in Ophthalmic Innovation Poised to Impact Global Eye Health Emmett T. Cunningham, Jr., M.D., PhD., M.P.H Department of Ophthalmology, California Pacific Medical Center Department of Ophthalmology, Stanford University School of Medicine Francis I. Proctor Foundation, UCSF School of Medicine West Coast Retina Medical Group Clarus Ventures, LLC
2 Financial Disclosures What Conflict of Interest? I work here in my spare time
3 Prognosticators
4 1 - Funding Largely / Increasingly Private (Private Equity / Corporate)
5 NEI Funding Flat, but At 1999 Level After Adjusting for Inflation $676K $411K Data provided by : Mala Dutta, Ph.D. Office of Translational Research, NEI
6 Total VC vs Biotech vs Device Investments ( ) $50 $45 $40 $35 $30 $25 $20 $15 $10 $5 $0 $47Bn Most Dramatic Increases NOT Biotech or Devices $5.6Bn $1.9Bn Total VC Dollars ($Bn) Biotech ($Bn) Device ($Bn) Source: PricewaterhouseCoopers, Silicon Valley Bank Courtesy Jon Norris
7 $10.0 $9.0 $8.0 $7.0 $6.0 $5.0 $4.0 $3.0 $2.0 $1.0 $6.0 Lifescience Venture Capital $7.3 Invested ( ) $9.1 $8.6 Invested ($Bn) Invested ($Bn) $6.6 $6.3 $7.7 $6.7 $6.7 $8.6 But, Biotech and Devices Also up ~ 30% $ Source: PricewaterhouseCoopers, Silicon Valley Bank Courtesy Jon Norris
8 Ophthalmic Investments Over Time ( *) # Deals # Biotech Deals # Device Deals VC Investment ($USD, Millions) Ophthalmic VC Funding Stable Overall ~ $ M / year / 15 Device Funding Slow ($M) *2015 figures through October SOURCE: Strategic Transactions business intelligence
9 NEI Funding Comparable to VC, but Modest in Comparison to Industry at Large Alcon ~ $670M ~1Bn VC ~ $380M ~$500M NEI ~ $665M ~$676M + etc
10 Translational Research Early Stage VCs Late Stage VCs Laboratory Research Clinical Research Treatments SBIR Industry
11 Understand Funding Sources / Risks Stage Source Of Funds NEI Pre-Seed Seed / Startup Early Late Founders Friends Family SBIR / Foundations Angels / Incubators VCs Institutional Investors (VC) Industry Funds Required Availability Of Funds $50K $100K $1M $100M Innovation Gap Risk High Risk Not drawn to scale! Low Modified after: Center for Venture Research University of New Hampshire
12 Private Placements ($M) VC Investment By Ophthalmic Indication ( *) 1, ,100 1, Number of Deals 0 0 *2015 figures through October SOURCE: Strategic Transactions Dollars ($ Millions) Number of Deals
13 2 Retina Enhanced Efficacy Through Improved Compliance (Sustained Release & Gene Therapy)
14 Global Causes of Blindness World Health Organization Undetermined Diabetic Retinopathy 1% Trachoma 3% 21% Retina 6% and growing Refractive Error Childhood 3% 4% Corneal Opacity 4% 51% Cataract AMD 5% Glaucoma 8%
15 Global Ophthalmic Procedures Glaucoma Filtering, Shunts, MIGs Laser Refractive Glaucoma Laser All Other Vitrectomies Laser Photocoagulation Retina 25.7M Cataract, RLE, Phakic IOLs 24.2M IVT Injections Source: Market Scope Estimates; Courtesy Dave Harmon. Market Scope
16 35 30 Global Ophthalmic Pharmaceutical Market Revenues by Indication $30.5 Bn 4.2 All Other 25 $20.9 Bn 3.7 Dry Eye Glaucoma Anti-VEGF/Retina ~ 54% Source: Market Scope Estimates; Courtesy Dave Harmon. Market Scope
17 Sustained-Release Corticosteroids
18 IVT a-vegf Injections. Courtesy Dr. Peter Karth and Dr. Marc Blumenkranz
19 (M) Global IVT a VEGF Injections 22.2M Most Growth OUS 17.6M M United States Outside United States Global Source: Market Scope Estimates; Courtesy Dave Harmon. Market Scope
20 Anti-VEGF for namd, DME, RVO
21 US Retina Specialist Treatment for Wet AMD 70.0% 60.0% 50.0% 61% Avastin 40.0% 30.0% 20.0% 10.0% 0.0% Q Q Q Lucentis Eylea Avastin Other 23% 12% 4% Eylea Lucentis Other Source: Market Scope Estimates; Courtesy Dave Harmon. Market Scope
22 Bevacizumab Ranibizumab
23 Strong Correlation Between Injection Frequency and Vision Gain Am J Ophthalmol 2014, 157: Study-Enforced Compliance Results in 4-5 Letter Mean Gain As Much As Effective Add-On Therapy
24 Sustained Release For Posterior Segment Phase 2b Ongoing Phase 2b 2Q2015 Simultaneous Detection of Chemokines, Cytokines, Growth Factors (eg, VEGF) Free Drug Release As Particles Erode Pre-IND Pre-IND Replenish Micropump TM
25 Ranibizumab (RBZ) Port Delivery System (RPDS) For Wet AMD LADDER Trial Phase 2 Data 1H2017
26 Gene Therapy in Ophthalmology At the Tipping Point? Sisyphus Snowball Tipping Point
27 Lux score, bilateral Positive Phase 3 Trial of SPK-RPE65 for the treatment of RPE65- mediated inherited retinal dystrophies (IRDs). BLA Submission Mean MT Lux Score/Level - Bilateral Leo A. The Gene Therapy Renaissance. April 18, *As measured by the change in bilateral mobility testing between baseline and one year. The multicenter, pivotal Phase 3 trial randomized 31 subjects with confirmed RPE65 gene mutations. The ITT population included 21 subjects in the intervention group and 10 in the control group. 1 0 Intervention BL D30 D90 D180 Y1 Study visit (mitt/safety population, n=29) Control
28 Phase 2 Data Anticipated 2016 X-linked retinoschisis (XLRS)
29 3 Glaucoma Enhanced Efficacy Through Improved Compliance (Sustained Release & MIGS)
30 Global Causes of Blindness World Health Organization Undetermined Diabetic Retinopathy 1% Trachoma 3% 21% Glaucoma 8% Refractive Error Childhood 3% 4% Corneal Opacity AMD 4% 5% Cataract 51% Glaucoma 8%
31 Global Ophthalmic Procedures Laser Refractive 2.8M Glaucoma Filtering, Shunts, MIGs Glaucoma Laser All Other Vitrectomies Laser Photocoagulation Cataract, RLE, Phakic IOLs IVT Injections Source: Market Scope Estimates; Courtesy Dave Harmon. Market Scope
32 35 30 Global Ophthalmic Pharmaceutical Market Revenues by Indication $30.5 Bn 4.2 All Other $20.9 Bn Dry Eye Glaucoma ~ 20% Anti-VEGF/Retina Source: Market Scope Estimates; Courtesy Dave Harmon. Market Scope
33 Am J Ophthalmol 2005; 140: Adherence Poor (< 50% by 6 months for most gtts) 2x higher with once daily therapy (prostaglandins) still low
34 1234 Eligibile Beneficiaries A Minority had Good Adherence Over Time 20% at 1 year 15% at 4 years
35 Sustained Release Drugs for Glaucoma Intracameral Bimatoprost SR P3 Intracameral Travoprost P2 Punctal Plug Latanaprost P2 Helios TM Insert Travoprost P2 Punctal Plug Travoprost P2
36 Founded MIGS Space istent istent - Approved for Glaucoma Surgery June, 2012 istent inject (G2) istent SUPRA (G3)
37 CyPass Micro-Stent PMA Submission Accepted by FDA October, 2015 CyPass Micro-Stent Pivotal COMPASS Trial Results Positive through Two Years
38 A Number of Followers in Clinical Development MicroShunt XEN Glaucoma Implant Hydrus Microstent
39 US Glaucoma Surgical Procedures (000) > 450, All Growth in MIGS In US Filtration Tube Shunts MIGs-Other (Forecast) 2020 Source: Market Scope Estimates; Courtesy Dave Harmon. Market Scope
40 Global Glaucoma Surgical Procedures (000) > 900, All Growth in MIGS Globally Filtration Tube Shunts MIGs-Other Source: Market Scope Estimates; Courtesy Dave Harmon. Market Scope
41 4 Cataract Pharaceutical Treatment
42 Global Causes of Blindness World Health Organization Undetermined 21% Diabetic Retinopathy 1% Trachoma 3% Refractive Error Childhood 3% 4% Corneal Opacity 4% AMD 5% 51% Cataract Glaucoma 8%
43 Global Ophthalmic Procedures Glaucoma Filtering, Shunts, MIGs Laser Refractive Glaucoma Laser All Other Vitrectomies Laser Photocoagulation Cataract, RLE, Phakic IOLs 22.2M IVT Injections Source: Market Scope Estimates; Courtesy Dave Harmon. Market Scope
44 Sterol eye drops reverse cataracts in mice Nature Jul 30;523(7562):
45 Sterols target crystallin to restore lens transparency in mouse models of cataracts Vehicle c29 c29 binds and stabilizes the dimer of cryab to reverse aggregation Lens Opacity (Cataract) Transparency Recovered Slit lamp biomicroscopy photographs from R120G cryab mice dosed topically with c29 eyedrops
46 5 India / China Centers of Innovation
47 An Eye on India and China 1.3 Bn 1.4 Bn
48 Necessity may be the mother in invention * BUT Plato Prosperity is the father of innovation.. A strong and sustained culture of innovation is predicated upon a strong economy with real or perceived discretionary spending *...let us begin and create in idea a State; and yet a true creator is necessity, which is the mother of our invention. The Republic, Book II, 369c, Plato
49 Global Contribution to World's GDP by Major Economies from 1 AD to 2003 AD Maddison A (2007), Contours of the World Economy I-2030AD, Oxford University Press, ISBN
50 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% Projected Relative Global Economies % 4% 3% 12% 18% 17% 6% 17% 11% 28% 23% 28% 12% 12% 15% 14% 12% 9% 18% 28% 16% Japan Other non-oecd Other OECD Euro Area India China USA
51
52 An Eye on India and China Emerging as Centers of Innovation Sun Pharma Acquires Insight - $48M Intas Pharmaceuticals Launches Razumab Similar to Ranabizumab Kanghong Biotech Launches Combercept Similar to Afilbercept
53 Opinions May Vary
54
Santen Acquisition of InnFocus, Developer of MicroShunt Glaucoma Implant Device
Santen Acquisition of InnFocus, Developer of MicroShunt Glaucoma Implant Device Akira Kurokawa President & CEO August 2, 2016 Copyright 2016 Santen Pharmaceutical Co., Ltd. All rights reserved. 1 External
More information2018 Glaukos Corporation. January 2018
2018 Glaukos Corporation 1 January 2018 Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect,
More informationOphthalmology is our singular focus Akira Kurokawa President & CEO, Santen Pharmaceutical Co., Ltd.
Ophthalmology is our singular focus Akira Kurokawa President & CEO, Santen Pharmaceutical Co., Ltd. J.P. Morgan Healthcare Conference January 8, 2018 Disclosure Notice 2 Information given in presentation
More informationSpark Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationOPT-302: a VEGF-C/VEGF-D Trap for wet AMD
OPT-302: a VEGF-C/VEGF-D Trap for wet AMD Ophthalmology Innovation Summit, Nov 12 2015 Circadian Technologies (ASX:CIR, OTCQX:CKDXY) Megan Baldwin PhD, CEO & MD megan.baldwin@opthea.com 2 Disclaimer Investment
More informationMinimally Invasive Glaucoma Surgical Procedures: Should I Incorporate Them Into My Practice?
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationOPHTHALMOLOGY FIELD ADVISORY COMMITTEE MEETING Virtual Teleconference October 20, :00 PM 3:00 PM EST
OPHTHALMOLOGY FIELD ADVISORY COMMITTEE MEETING Virtual Teleconference October 20, 2017 12:00 PM 3:00 PM EST Reference/Issue 1:00 Pharmacy EST Dr. Linda Margulies Discussion Guests: Deb Khachikian, PharmD,
More informationSpark Therapeutics, Inc.
Spark Therapeutics, Inc. Corporate Overview November 2017 1 Forward looking statements This presentation contains "forward looking statements" within the meaning of the Private Securities Litigation Reform
More informationAflibercept (Eylea) Benefit assessment according to 35a Social Code Book V 1
IQWiG Reports Commission No. A12-19 Aflibercept (Eylea) Benefit assessment according to 35a Social Code Book V 1 Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Aflibercept (Eylea)
More informationMomenta Pharmaceuticals, Inc. 36 th Annual J.P. Morgan Healthcare Conference
Momenta Pharmaceuticals, Inc. 36 th Annual J.P. Morgan Healthcare Conference January 8, 2018 Forward-Looking Statements This presentation contains forward-looking statements about our financial outlook,
More informationIntraocular Lens (IOL): Market Shares, Strategies, and Forecasts, Worldwide, Nanotechnology, 2013 to 2018
Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > Intraocular Lens (IOL): Market Shares, Strategies, and Forecasts, Worldwide, Nanotechnology, 2013 to 2018 Intraocular
More informationJEFFERIES HEALTHCARE CONFERENCE
JEFFERIES HEALTHCARE CONFERENCE JUNE 10, 2016 Evolution in Visual Freedom FORWARD-LOOKING STATEMENTS BUILDING A FOUNDATION FOR CONSISTENT GROWTH All statements in this presentation that are not statements
More informationALLERGAN ENTERS STRATEGIC R&D ALLIANCE WITH EDITAS MEDICINE TO DISCOVER AND DEVELOP CRISPR GENE EDITING PROGRAMS FOR OCULAR DISEASES
ALLERGAN ENTERS STRATEGIC R&D ALLIANCE WITH EDITAS MEDICINE TO DISCOVER AND DEVELOP CRISPR GENE EDITING PROGRAMS FOR OCULAR DISEASES Novel Development Programs for Potential Treatments of Serious Ocular
More informationInaugural Fraunhofer Delaware Technology Summit
Inaugural Fraunhofer Delaware Technology Summit Energy and Life Sciences Solu
More informationSTRATEGIC PLANNING FOR OPHTHALMOLOGY PRACTICES. My Background. Peter Wasserman, MD, MBA InSight Healthcare Solutions, LLC. Financial Disclosure
STRATEGIC PLANNING FOR OPHTHALMOLOGY PRACTICES Financial Disclosure Peter Wasserman, MD, MBA InSight Healthcare Solutions, LLC My Background http://insight-healthcare.com Comprehensive ophthalmologist
More informationWhat is New on the Regulatory Front?
What is New on the Regulatory Front? Veronica Miller, PhD Forum for Collaborative Research UC Berkeley SPH Outline Innovation in regulatory science Regulatory challenges in NASH Opportunities for innovation
More informationThe Drug Development Process and Design of Clinical Trials
The Drug Development Process and Design of Clinical Trials Darlene Kitterman, MBA Director, Investigator Support & Integration Services September 24, 2014 Clinical Trial Design Guidance Clinical Trial:
More informationBrazil Gastric Balloon Procedures Outlook to 2020
Brazil Gastric Balloon Procedures Outlook to 2020 Reference Code: GDMECC0472PDB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 3 1.2 List of Figures...
More informationCIBA Vision Corporation Market Share Analysis
CIBA Vision Corporation Market Share Analysis Reference Code: GDME0740CDB Publication Date: January 2013 GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold
More informationREGENXBIO Inc. Ticker: RGNX
REGENXBIO Inc. Ticker: RGNX I know what you are thinking. You are about to read another biotech report with more acronyms than words you know the definitions. I promise you this report is written in layman
More informationThe importance of regulatory science in a societal and industrial perspective Annual Conference CORS 24 November 2016
The importance of regulatory science in a societal and industrial perspective Annual Conference CORS 24 November 2016 Marianne Kock, Head of Global Regulatory Affairs & Managing Director, Ferring Pharmaceuticals
More informationUnder this license, you are approved to manufacture aflibercept drug substance intermediate, drug substance, and formulated bulk at
DEPARTMENT OF HEALTH AND HUMAN SERVICES Silver Spring MD 20993 Our STN: BL 125387/0 BLA APPROVAL November 18, 2011 Regeneron Pharmaceuticals, Inc. Attention: Laura Pologe, Ph.D. Associate Director, Regulatory
More informationSymposium INTERNATIONAL SCIENTIFIC SYMPOSIUM: WHAT S NEW IN REFRACTIVE EYE SURGERY
Symposium INTERNATIONAL SCIENTIFIC SYMPOSIUM: WHAT S NEW IN REFRACTIVE EYE SURGERY PREFACE Dear colleagues and friends, The Department of Medical Sciences of the Croatian Academy of Sciences and Arts
More informationIntroducing the envista IOL. Dr Kerrie Meades PersonalEYES Pty Ltd
Introducing the envista IOL Dr Kerrie Meades PersonalEYES Pty Ltd envista IOL Basic Features Hydrophobic acrylic IOL, single piece 6.0mm aspheric neutral optic, modified C haptic 12.5mm overall length
More informationSeptember 11, Dear Administrator Verma:
September 11, 2017 The Honorable Seema Verma Administrator Centers for Medicare & Medicaid Services Department of Health and Human Services Attention: CMS-1676-P Mail Stop C4-26-05 7500 Security Boulevard
More informationA Primer for budding entrepreneurs: I think I have a great idea, now what? Background on Confluent The Primer Discussion
A Primer for budding entrepreneurs: I think I have a great idea, now what? Background on Confluent The Primer Discussion Company Overview Platform technology of in situ polymerized biomaterials and delivery
More informationYASHAJIT SAHA & ABHISHEK SHARMA, SUBJECT MATTER EXPERTS, RESEARCH & ANALYTICS ADVANCED ANALYTICS: A REMEDY FOR COMMERCIAL SUCCESS IN PHARMA.
YASHAJIT SAHA & ABHISHEK SHARMA, SUBJECT MATTER EXPERTS, RESEARCH & ANALYTICS ADVANCED ANALYTICS: A REMEDY FOR COMMERCIAL SUCCESS IN PHARMA wns wns ADVANCED ANALYTICS: A REMEDY FOR COMMERCIAL SUCCESS IN
More informationCORPORATE NEWS EARNINGS PAION AG PUBLISHES GROUP QUARTERLY STATEMENT FOR THE FIRST NINE MONTHS OF 2016
CORPORATE NEWS EARNINGS PAION AG PUBLISHES GROUP QUARTERLY STATEMENT FOR THE FIRST NINE MONTHS OF 2016 Positive remimazolam data in pivotal U.S. Phase III study for procedural sedation during colonoscopy
More information8. Clinical Trial Assessment Phase II
8. Clinical Trial Assessment Phase II Junko Sato, PhD Office of New Drug I, PMDA Disclaimer: The information within this presentation is based on the presenter s expertise and experience, and represents
More informationMaximizing Market Access: THE 5 MOST CRITICAL QUESTIONS TO ASK WHEN LAUNCHING A SPECIALTY DRUGS
Maximizing Market Access: THE 5 MOST CRITICAL QUESTIONS TO ASK WHEN LAUNCHING A SPECIALTY DRUGS by Jan Nielsen, division president, Access & Patient Support Are You Asking the Right Questions? We ve all
More informationThe heyelight in ophthalmic surgery MEGATRON
The heyelight in ophthalmic surgery S3 MEGATRON GEUDER Precision made in Germany GEUDER AG is one of the leading manufacturers of ophthalmic surgical instruments and systems in Germany and in the international
More informationDrug Development: Why Does it Cost so Much? Lewis J. Smith, MD Professor of Medicine Director, Center for Clinical Research Associate VP for Research
Drug Development: Why Does it Cost so Much? Lewis J. Smith, MD Professor of Medicine Director, Center for Clinical Research Associate VP for Research Drug Development Process by which new chemical entities
More informationIT S A GLOBAL LEADER. IT S PROVEN.
isert Preloaded IOL System IT S A GLOBAL LEADER. IT S PROVEN. IT S isert. isert delivers the combination of simple operation, outstanding visual quality, and procedural efficiency. LEADERSHIP, WITH VISION
More informationNational Foundation for Women Legislators Annual Meeting September 12, 2015 Tara Ryan Vice President, State Government Advocacy
From Hope to Cures: The Value of Biopharmaceutical Innovation National Foundation for Women Legislators Annual Meeting September 12, 2015 Tara Ryan Vice President, State Government Advocacy HIV/AIDS: Then
More informationFrance Pressure Relief Devices Market Outlook to 2020
France Pressure Relief Devices Market Outlook to 2020 Reference Code: GDMECC0869DB Publication Date: October 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 3 1.2 List of
More informationHow to Build a Molecular Testing Laboratory: Key Strategic & Operational Considerations. The complete guide to developing or expanding your lab
How to Build a Molecular Testing Laboratory: Key Strategic & Operational Considerations The complete guide to developing or expanding your lab Includes step-by-step plans for basic and full-service MDx
More informationSAMPLE. Mexico Orthopedic Prosthetics Market Outlook to Reference Code: GDMECC0156DB. Publication Date: February 2014
Mexico Orthopedic Prosthetics Market Outlook to 2020 Reference Code: GDMECC0156DB Publication Date: February 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 3 1.2 List of
More informationRWE from pre-clinical to launch. RWE from pre-clinical to launch. Standard of care Unmet needs. Disease burden Budget impact.
Real Real World World Data Data Across Across the the Product Product Lifecycle: Lifecycle: RWE from pre-clinical to launch RWE from pre-clinical to launch Standard of care Unmet needs Disease burden Budget
More informationWhat is an Investigational Drug? 21CFR312.3(b)
Review of the Investigational Drug and Device Regulations Changes to the RSRB Online Submission System (ROSS) Application for Drugs and Devices Kelley O'Donoghue Donoghue, Director OHSP, MPH, CIP and Tiffany
More informationHealth Care Logistics: an Enabler of Change BioLogistics in a Changing Healthcare World Northwestern University Transportation Center
Health Care Logistics: an Enabler of Change BioLogistics in a Changing Healthcare World Northwestern University Transportation Center Dave Bode VP, Health Care Solutions DSC Logistics April 20, 2016 Health
More informationBRIC Surgical Sutures Market Outlook to 2020
BRIC Surgical Sutures Market Outlook to 2020 Reference Code: GDMECR0270DB Publication Date: October 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 5 1.2 List of Figures...
More informationOptimal Use of Minimally Invasive Glaucoma Surgery: A Health Technology Assessment Project Protocol
CADTH OPTIMAL USE REPORT Optimal Use of Minimally Invasive Glaucoma Surgery: A Health Technology Assessment Project Protocol PROSPERO Registration Number: CRD42018082223 Service Line: Optimal Use Issue:
More informationSevere Stargardt disease with peripapillary sparing
www.edoriumjournals.com CLINICAL IMAGES PEER REVIEWED OPEN ACCESS Severe Stargardt disease with peripapillary sparing Heather Leisy, Meleha Ahmad, Nathaniel Tracer, R. Theodore Smith ABSTRACT Abstract
More informationFosterly's Startup Census is intended to be completed by startup and creative economy founders and executives in DC, Maryland, and Virginia.
Intro Fosterly's Startup Census is intended to be completed by startup and creative economy founders and executives in DC, Maryland, and Virginia. We have taken several steps to decrease the amount of
More informationEnergy Perspectives for Asia
Energy Perspectives for Asia By Rajiv Ranjan Mishra Nov 21, 2017 Energy Asia Population Asia 4.06 billion 55% of World 8X of EU Expected to be 8.5 billion by 2030 Source: World Bank, 2016; UN GDP Per Capita
More informationPerspectives on BioPharma Innovation
Perspectives on BioPharma Innovation David Thomas, CFA Senior Director, Industry Research & Policy Analysis BIO Presented to members of the National Conference of State Legislatures June 2016 BIOTECHNOLOGY
More informationRegulatory Pathways. Devices vs. Drugs Are there roles for registries? John Laschinger, MD CDRH/ODE/DCD/SHDB
Regulatory Pathways Devices vs. Drugs Are there roles for registries? John Laschinger, MD CDRH/ODE/DCD/SHDB johnlaschinger@fda.hhs.gov 1 Disclosures and Disclaimer John C. Laschinger, M.D. I am a full
More informationWITA/GWU TRADE SEMINAR September 29, 2016 Washington D.C. RICHARD KJELDGAARD INTELLECTUAL PROPERTY AND TRADE CONSULTANT
WITA/GWU TRADE SEMINAR September 29, 2016 Washington D.C. RICHARD KJELDGAARD INTELLECTUAL PROPERTY AND TRADE CONSULTANT Pharmaceutical IP Policy Issues Economics - Business Model IP TPP Global Challenges
More informationThe Lancet Publishes Results from the Landmark Phase III Rivaroxaban Study RECORD2
News Release Bayer HealthCare AG Corporate Communications 51368 Leverkusen Germany Phone +49 214 30 1 www.news.bayer.com Venous Blood Clot Prevention after Hip Replacement Surgery: The Lancet Publishes
More informationISO Ophthalmic optics Contact lenses and contact lens care products Guidance for clinical investigations
INTERNATIONAL STANDARD ISO 11980 Third edition 2012-11-15 Ophthalmic optics Contact lenses and contact lens care products Guidance for clinical investigations Optique ophtalmique Lentilles de contact et
More informationFDA s Center for Devices and Radiological Health: Strategic Priorities for 2017 and Beyond
FDA s Center for Devices and Radiological Health: Strategic Priorities for 2017 and Beyond Jeff Shuren, MD, JD Center for Devices and Radiological Health U.S. Food and Drug Administration May 4, 2017 1
More informationDefining Clinical Benefit in Clinical Trials: FDA Perspective
Defining Clinical Benefit in Clinical Trials: FDA Perspective Jessica J. Lee, MD, MMSc Medical Team Leader Division of Gastroenterology and Inborn Errors Products Center for Drug Evaluation and Research
More informationRegulatory Considerations and Trends Europe and the U.S.
Regulatory Considerations and Trends Europe and the U.S. Professor Kjell Strandberg MD PhD Chairman NDA Advisory Board, NDA Regulatory Science Ltd UK Former CPMP Member and Director General Medical Products
More informationHealthcare s New Change-Maker: The CFO
The role of hospital chief financial officer has changed dramatically over the last 50 years. No longer simply responsible for managing the hospital s finances, today s CFO is a change agent, an indispensable
More informationJune 7, Harold E. Varmus, MD Director National Cancer Institute 31 Center Drive Building 31 Room 11A48 MSC 2590 Bethesda, Maryland
Harold E. Varmus, MD Director National Cancer Institute 31 Center Drive Building 31 Room 11A48 MSC 2590 Bethesda, Maryland 20892-2590 Dear Harold: Thank you, again, for taking the time to come to ASCO
More informationChin Koerner Executive Director US Regulatory and Development Policy
Chin Koerner Executive Director US Regulatory and Development Policy Novartis Pharmaceuticals Corporation 1700 Rockville Pike Suite 510 Rockville, MD 20852 Tel 301.468.5607 Fax 301.468.5614 Email: Chin.Koerner@novartis.com
More informationZacks Small-Cap Research
Zacks Small-Cap Research November 27, 2017 Brian Marckx, CFA bmarckx@zacks.com Ph (312) 265-9474 scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 EyeGate Pharmaceuticals (EYEG-NASDAQ) EYEG: Cataract
More informationKonica Minolta to Acquire Invicro (US)
Konica Minolta to Acquire Invicro (US) Acceleration of expansion of precision medicine business Offering new value for drug discovery and development in immuno-oncology and neurodegenerative disease September
More informationFirst-in-Class Bispecific Antibodies For Cancer Immunotherapy
First-in-Class Bispecific Antibodies For Cancer Immunotherapy 2015 Company Highlights Vision Team Platform Pipeline Partners To dominate the bispecific antibody space in immunooncology through unique pipeline
More informationCopyright. Jeremiah J. Kelly (2015). All rights reserved. Further dissemination without express written consent strictly prohibited.
Statutory Framework for Biologics Drugs Investigational Use Application IND Pre-Market Approval Applications 505(b)(1) NDA 505(b)(2) NDA 505(j) ANDA Over-the-Counter (OTC) Non- Rx Drugs Monograph Biologics
More informationState of the Clinical Trials Industry
State of the Clinical Trials Industry A Sourcebook of Charts and Statistics 2009 SM 100 N. Washington St., Ste. 301 Boston, MA 02114 www.centerwatch.com ix xxxv 1 41 L I S T O F F I G U R E S A N D T A
More informationBaek, Kyung-min. Recombinant Protein Products Division. Ministry of Food and Drug Safety
Baek, Kyung-min Recombinant Protein Products Division Ministry of Food and Drug Safety About Ministry of Food and Drug Safety Regulation for Biosimilar Principle of Biosimilar Approach Status of Biosimilar
More informationA world in transition: PwC s 2017 APEC CEO Survey, November APEC CEO Survey. Indonesia findings.
A world in transition: PwC s 2017 APEC CEO Survey, November 2017 2017 APEC CEO Survey Indonesia findings www.pwc.com/apec Key themes Making of the workforce of the future An operating model for a fluid
More informationBio-Pharma: China A Look at The FUTURE: 4 th & 5 th Generation Global Strategies
Global Strategy Global Challenges Executable Solutions Bio-Pharma: China 2010-2020 A Look at The FUTURE: 4 th & 5 th Generation Global Strategies France Houdard Managing Director January 2010 Table of
More informationGermany Tissue Engineered - Skin Substitutes Market Outlook to 2020
Germany Tissue Engineered - Skin Substitutes Market Outlook to 2020 Reference Code: GDMECC0884DB Publication Date: October 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables...
More informationBuild With VICTUS. Build Your Patient Offerings. Build Your Premium Practice.
Build Your Patient Offerings. Build Your Premium Practice. Build With VICTUS. The VICTUS femtosecond laser workstation delivers multi-mode versatility for cataract and corneal procedures on a single platform.
More informationAravind Eye Hospital Case Study
Aravind Eye Hospital Case Study US Army-Baylor Masters of Health Administration Marketing Management MMKT 5470 18 February 2015 CPT James Beheler MAJ Philip Durando CPT Elvis Gonzalez CPT Stephanie Kessinger
More informationLocal Market Intelligence:
Local Market Intelligence: Store level insights for SMBs; distribution opportunities for partners 27 th February 2017 Delivering Insights for Impact Local Market Intelligence gives merchants a deep set
More informationIntroduction to Clinical Research
Introduction to Clinical Research What is Clinical Research? Clinical research is medical research that involves people like you. People volunteer to participate in carefully conducted investigations that
More informationFDA Drug Approval Process Vicki Seyfert-Margolis, Ph.D.
Speaker Comparing The Effectiveness Of New Drugs: Should The FDA Be Asking 'Does It Work' Or 'Does It Work Better'? Vicki L. Seyfert-Margolis, PhD Senior Advisor, Science Innovation and Policy U.S. Food
More informationSection I: Pharmaceuticals and Medical Devices
SUPPLEMENT on HEALTHCARE INNOVATION Visionary Goals and Recommendations 51th Japan-U.S. Business Conference Japan-U.S. Business Council / U.S.-Japan Business Council November 14, 2014 The R&D-based pharmaceutical
More informationBuild With VICTUS. Build Your Patient Offerings. Build Your Premium Practice.
Build Your Patient Offerings. Build Your Premium Practice. Build With VICTUS. The VICTUS Femtosecond Laser Workstation delivers multi-mode versatility for cataract and corneal procedures on a single platform.
More informationBUILDING AN ANNUAL STRATEGIC PLAN
BUILDING AN ANNUAL STRATEGIC PLAN Mike Trier No Financial Interest CEO of Horizon Eye Specialists & LASIK Center and Eye Surgery Center at the Biltmore in Phoenix, AZ Director of Assil Eye Institute and
More informationSAMPLE. Bracco Imaging S.p.A.Market Share Analysis. Bracco Imaging S.p.A. Market Share Analysis GDME0639CDB / Published January 2013
Market Share Analysis Reference Code: GDME0639CDB Publication Date: January 2013 GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form Page 1 Table
More informationUnderstanding the Gene Therapy Market Today
Understanding the Gene Therapy Market Today February 2017 Author: Richard Tinsley, Strategy Partner C International Contents A Case Study Utilizing Gene Therapy to Correct Genetic Vision Problem 1 Learning
More informationMedidée Services SA. Nano-Tera.ch. 05 February 2015 part 8. PMA, 510k, IDE. Pierre-Alain Sommer
Nano-Tera.ch 05 February 2015 part 8 PMA, 510k, IDE Pierre-Alain Sommer Pierre-alain.sommer@medidee.com www.medidee.com Nano-Tera 2015 05.02.2015 USA/FDA Pre Market Approval System - PMA, Pre Market Notifcation
More informationEU support for Health Research from FP6 to FP7
EU support for Health Research from FP6 to FP7 Stéphane Hogan Head of Biotechnology Unit Directorate for Health Research DG Research - European Commission Valencia - 15 September 2006 EU research programmes
More informationDUCHENNE MUSCULAR DYSTROPHY CLINICAL DEVELOPMENT PROGRAM
DUCHENNE MUSCULAR DYSTROPHY CLINICAL DEVELOPMENT PROGRAM Dana R. Martin, PharmD Sarepta Therapeutics PPMD ANNUAL CONNECT CONFERENCE ORLANDO, FLORIDA JUNE 27, 2016 FORWARD LOOKING STATEMENTS This presentation,
More informationRegulatory Challenges and Threats in Orphan Drug Development Are Ultra Orphans Easy?
Regulatory Challenges and Threats in Orphan Drug Development Are Ultra Orphans Easy? EPLS September 24, 2014 Ulrich Granzer Granzer Regulatory Consulting & Services The Challenge: What needs to be done
More informationComments from the FDA Working Group on SUBGROUP ANALYSES. Estelle Russek-Cohen, Ph.D. U.S. Food and Drug Administration Center for Biologics
Comments from the FDA Working Group on SUBGROUP ANALYSES Estelle Russek-Cohen, Ph.D. U.S. Food and Drug Administration Center for Biologics 1 Outline An intro to FDA EMA and FDA on subgroups Companion
More informationThe Economics of New Drug Development: Costs, Risks, and Returns
The Economics of New Drug Development: Costs, Risks, and Returns Joseph A. DiMasi, Ph.D. Tufts Center for the Study of Drug Development Tufts University The New England Drug Metabolism Group Spring Meeting
More informationPHARMA CONGRESS. Pharmacovigilance and Drug Safety: Assessing Future Regulatory and Compliance Developments. October 28, 2008
PHARMA CONGRESS October 28, 2008 Pharmacovigilance and Drug Safety: Assessing Future Regulatory and Compliance Developments Beverly H. Lorell, MD Senior Medical & Policy Advisor King & Spalding LLP Assessing
More informationGlobal Forum on Competition
Unclassified DAF/COMP/GF/WD(2014)51 DAF/COMP/GF/WD(2014)51 Unclassified Organisation de Coopération et de Développement Économiques Organisation for Economic Co-operation and Development 14-Feb-2014 English
More informationBuilding An Annual Strategic Plan
Financial Disclosure Building An Annual Strategic Plan Mike Trier No Financial Interest CEO of Horizon Eye Specialists & LASIK Center and Eye Surgery Center at the Biltmore in Phoenix, AZ Mike Trier Executive
More informationFDA S DRAFT GUIDANCE ON MULTIPLE ENDPOINTS IN CLINICAL TRIALS: OVERVIEW, RECEPTION AND NEXT STEPS. John Scott, Ph.D. FDA/CBER 5 October 2017
FDA S DRAFT GUIDANCE ON MULTIPLE ENDPOINTS IN CLINICAL TRIALS: OVERVIEW, RECEPTION AND NEXT STEPS John Scott, Ph.D. FDA/CBER 5 October 2017 Disclaimer 2 This presentation reflects the views of the author
More informationPharma R&D and Patents support Health Care & Economy
Pharma R&D and Patents support Health Care & Economy Konstantinos Μ. Frouzis President of SFEE, V.P & Gen. Manager of Novartis Hellas April 28 th, 2014 Intellectual Property Patents: The vehicle for innovation
More informationAxel Hoos, M.D., Ph.D., SVP, Therapeutic Area Head for Oncology R&D and Head of Immuno Oncology, GSK
Magazine Article September 1, 2016 Source: Life Science Leader By Rob Wright, Chief Editor, Life Science Leader Follow Me On Twitter @RfwrightLSL Is Oncology Back At GSK? Did It Ever Leave? Axel Hoos,
More informationChallenges and Opportunities in Pharma: Perspective for an Emerging Middle East April 24th, 2015
Challenges and Opportunities in Pharma: Perspective for an Emerging Middle East 2020 April 24th, 2015 Content Pharma Market Landscape Global Pharma Market Market Categories Middle East Markets Major Challenges
More informationInsight to Gene Techno Science Co.,Ltd
Unlimited drug discovery from the beginning Ticker symbol: 4584 Insight to Gene Techno Science Co.,Ltd November 2017 2 Corporate Overview Chief Executive Founded March 2001 Masaharu Tani, President Listed
More informationThe Device Side of Combination Products
The Device Side of Combination Products Technical and Regulatory Challenges in Life Cycle Management Bob Laughner Associate Director, Combination Products 04 May 2016 What are combination products? Combination
More information